Differential Diagnosis of Benign and Malignant Lung Lesions via Applying Artificial Intelligence Analysis of Gene Information in Peripheral Blood

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900026445

Enrollment

Unknown

Registered

2019-10-10

Start date

2019-10-12

Completion date

Unknown

Last updated

2019-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary malignancy

Interventions

Gold Standard:Pathological examination

Index test:Artificial&#32

Intelligence&#32

Analysis&#32

of&#32

Gene&#32

Information&#32

in&#32

Peripheral&#32

Blood

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18 and 80 years; 2. Suspected pulmonary malignancy patients or benign pulmonary disease patients; 3. Planned to receive surgical treatment; 4. Sufficient blood samples and tissue samples for analysis; 5. Signed informed consent, with good compliance.

Exclusion criteria

Exclusion criteria: 1. Recurrent pulmonary malignancy patients; 2. Lysis of blood sample; 3. Blood sample was not processed within 24 hours; 4. Pregnant or lactating patients; 5. Received any anti-tumor therapy before surgery; 6. Patients with prior cancer history.

Design outcomes

Primary

Measure	Time frame
Pathological diagnosis;Gene Information in Peripheral Blood;SEN, SPE, ACC, +LR, -LR, AUC of ROC;	—

Countries

China

Contacts

Public ContactGuangyuan Hu

Department of Oncology, Tongji Hospital affiliated to Tongji Medical College, Huazhong University of Science and Technology

huguangyuan2018@sohu.com+86 13886000095

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026